Roadmap for new practitioners to navigate the multiple myeloma landscape.
Anti-CD38-targeting antibodies
Immunomodulators
Multiple myeloma
Proteosome inhibitors
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
27
06
2022
revised:
17
08
2022
accepted:
05
09
2022
entrez:
27
9
2022
pubmed:
28
9
2022
medline:
28
9
2022
Statut:
epublish
Résumé
Multiple myeloma (MM) is a blood cancer in which monoclonal plasma cells cause end organ damage resulting in hypercalcemia, renal failure, anemia, and bone lesions. MM is considered incurable, however, recent advances in treatment have improved survival. Historically, MM has been treated with immunomodulatory drugs (IMiDs), proteosome inhibitors (PIs), and corticosteroids. While newer therapeutic approaches such as monoclonal antibodies and cellular therapies have broadened the treatment horizon, the selection and sequencing of these therapies has become more complex. This review aims to help advanced practice providers navigate through the diagnosis, staging, treatment, and supportive care considerations in the MM space.
Identifiants
pubmed: 36164513
doi: 10.1016/j.heliyon.2022.e10586
pii: S2405-8440(22)01874-6
pmc: PMC9508512
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e10586Informations de copyright
© 2022 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Oncol Ther. 2021 Jun;9(1):69-88
pubmed: 33615426
Front Immunol. 2018 Nov 15;9:2616
pubmed: 30498492
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):37-45
pubmed: 34889430
Oncology (Williston Park). 2011 Nov 15;25 Suppl 2:19-24
pubmed: 25188479
Curr Oncol. 2021 Jan 21;28(1):640-660
pubmed: 33494319
Mol Cancer Ther. 2011 Nov;10(11):2034-42
pubmed: 22072815
Lancet Haematol. 2020 May;7(5):e370-e380
pubmed: 32213342
Target Oncol. 2021 Sep;16(5):675-686
pubmed: 34351561
JAMA. 2017 Jan 3;317(1):48-58
pubmed: 28030702
Lancet Oncol. 2018 Jul;19(7):953-964
pubmed: 29866475
Hematol Rep. 2020 Dec 18;12(3):9054
pubmed: 33408844
J Oral Biol Craniofac Res. 2013 Jan-Apr;3(1):25-30
pubmed: 25737876
Leukemia. 2010 Jan;24(1):22-32
pubmed: 19907437
Drugs. 2017 Apr;77(5):505-520
pubmed: 28205024
Leukemia. 2012 Feb;26(2):349-55
pubmed: 21836613
Lancet Oncol. 2020 Oct;21(10):1317-1330
pubmed: 32866432
Onco Targets Ther. 2019 Jul 18;12:5813-5822
pubmed: 31410026
Blood. 2011 Jun 9;117(23):6063-73
pubmed: 21447828
Lancet Oncol. 2019 Dec;20(12):1760-1772
pubmed: 31668592
N Engl J Med. 2021 Feb 25;384(8):705-716
pubmed: 33626253
J Clin Oncol. 2018 Oct 20;36(30):3043-3054
pubmed: 30179565
Haematologica. 2020 Apr;105(4):1067-1073
pubmed: 31792034
J Clin Oncol. 2020 Nov 1;38(31):3698-3715
pubmed: 32716741
Lancet Oncol. 2018 Mar;19(3):370-381
pubmed: 29429912
Clin Lymphoma Myeloma Leuk. 2018 May;18(5):335-345
pubmed: 29610030
Blood Adv. 2020 Jan 28;4(2):422-431
pubmed: 31990333
Blood Cancer J. 2021 May 12;11(5):89
pubmed: 33980831
Blood. 2010 Apr 22;115(16):3416-7
pubmed: 20413666
Haematologica. 2008 Dec;93(12):1908-11
pubmed: 18768528
Blood Adv. 2020 Dec 8;4(23):5988-5999
pubmed: 33284948
Lancet. 2019 Jan 19;393(10168):253-264
pubmed: 30545780
Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e777-e781
pubmed: 32660902
Lancet Oncol. 2010 Jan;11(1):29-37
pubmed: 19853510
Br J Haematol. 2018 Nov;183(4):538-556
pubmed: 30450656
Lancet Oncol. 2020 Dec;21(12):1630-1642
pubmed: 33129376
Blood Adv. 2018 Jul 10;2(13):1608-1615
pubmed: 29986853
N Engl J Med. 2019 Aug 22;381(8):727-738
pubmed: 31433920
Cancer Manag Res. 2020 Aug 26;12:7891-7903
pubmed: 32904669
N Engl J Med. 2015 Aug 13;373(7):621-31
pubmed: 26035255
J Am Dent Assoc. 2006 Aug;137(8):1144-50
pubmed: 16873332
N Engl J Med. 2011 Mar 17;364(11):1046-60
pubmed: 21410373
Ann Hematol. 2019 Jan;98(1):19-28
pubmed: 30073393
Ann Oncol. 2012 Jan;23(1):193-200
pubmed: 21427065
J Blood Med. 2021 May 25;12:327-336
pubmed: 34079412
Blood. 2018 Dec 6;132(23):2456-2464
pubmed: 30249784